852. Deputy Ken O'Flynn asked the Minister for Health the total financial value of rejected PCRS claims for respiratory medicines that remained unpaid in each of the years 2020 t0 2025, and to date in 2026, broken down by year; the reason such a high proportion of rejected claims are never subsequently corrected or reclaimed; whether an assessment has been carried out into the impact of these unrecovered claims on pa…
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions asked by Ken O'Flynn under the heading Primary Care Services.
38 questions match, newest first.
860. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No. 773 of 21 April 2026, to confirm whether the HSE maintains any database recording clinical outcomes for patients treated under the Treatment Abroad Scheme, given that the data referenced in the reply to PQ28074/26 relates only to activity and expenditure, not outcomes. [49306/26]
861. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No's 774,784,785,786,789 of 21 April 2026, to identify the body or unit with national responsibility for clinical outcomes oversight under the Treatment Abroad Scheme, given that this was not addressed in the reply to PQ28106/26. [49307/26]
862. Deputy Ken O'Flynn asked the Minister for Health further to Parliamentary Question No's 774,784,785,786,789 and 788 of 21 April 2026, the mechanisms that exist to monitor follow-up care for patients returning to the State after Treatment Abroad Scheme procedures, given that the reply to PQ28076/26 and PQ28105/26 described only the application process, not post-treatment monitoring. [49308/26]
2336. Deputy Ken O'Flynn asked the Minister for Health the number of rejected claims recorded under the PCRS in each of the years 2023, 2024, 2025 and to date in 2026 for respiratory medicines including salbutamol, ipratropium products, inhaled corticosteroids and nebuliser products; the number subsequently paid following resubmission; the most common reasons for rejection; and if she will make a statement on the mat…
2337. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has undertaken any analysis, audit, review or monitoring of rejected PCRS claims relating to respiratory medicines since 2023; whether any trends, recurring errors, reimbursement issues or patient-access concerns have been identified; and if she will make a statement on the matter. [43675/26]
1023. Deputy Ken O'Flynn asked the Minister for Health the average time taken to resolve and reimburse corrected pharmacy claims originally rejected due to administrative or submission errors. [36743/26]
1024. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has conducted any assessment of the financial or operational impact of rejected pharmacy claims on independent community pharmacies. [36744/26]
1025. Deputy Ken O'Flynn asked the Minister for Health whether any national targets or key performance indicators exist to reduce the proportion of rejected or unpaid pharmacy claims attributable to administrative or submission errors. [36745/26]
1026. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has considered introducing additional automated pre-submission validation systems to reduce pharmacy claim rejection rates. [36746/26]
1028. Deputy Ken O'Flynn asked the Minister for Health whether any review has been undertaken into whether pharmacy software compatibility issues contribute disproportionately to rejected or unpaid claims. [36748/26]
1029. Deputy Ken O'Flynn asked the Minister for Health the financial impact on annual PCRS expenditure arising from the 2022 steri-neb salamol price uplift. [36753/26]
1088. Deputy Ken O'Flynn asked the Minister for Health the percentage of primary care laboratory requests currently submitted electronically versus paper-based requests; and if she will make a statement on the matter. [36993/26]
1091. Deputy Ken O'Flynn asked the Minister for Health whether any national guidance exists regarding appropriate intervals for repeat lipid profile testing in primary care; and if she will make a statement on the matter. [36996/26]
765. Deputy Ken O'Flynn asked the Minister for Health whether the Primary Care Reimbursement Service maintains product-specific data on rejected or unpaid pharmacy claims under the general medical services and drugs payment schemes; and if not, whether there are plans to introduce such data tracking mechanisms [28064/26]
766. Deputy Ken O'Flynn asked the Minister for Health whether any proportion of rejected or unpaid claims for salbutamol nebules in 2024 and 2025 can be disaggregated from general rejection categories; and if so, to provide the number and percentage of such claims. [28065/26]
767. Deputy Ken O'Flynn asked the Minister for Health to provide a detailed breakdown of the reasons for rejected or unpaid pharmacy claims under the general medical services scheme in 2024 and 2025, including the number of claims in each category and whether such categories are linked to specific medicines. [28066/26]
768. Deputy Ken O'Flynn asked the Minister for Health the oversight mechanisms that are in place to monitor rejection rates for commonly prescribed medicines under the general medical services scheme, including respiratory medications; and whether any review of rejection patterns has been conducted in the past three years. [28067/26]
769. Deputy Ken O'Flynn asked the Minister for Health whether any audit or validation exercise has been conducted on the accuracy and consistency of claim rejections by the Primary Care Reimbursement Service in 2024 or 2025; and if so, to provide details of the findings and any actions taken. [28068/26]
770. Deputy Ken O'Flynn asked the Minister for Health whether the Health Service Executive assesses the patient impact of rejected or unpaid pharmacy claims under the general medical services scheme; and if so, to outline the methodology used and any findings in relation to essential medicines. [28069/26]
771. Deputy Ken O'Flynn asked the Minister for Health whether any medicines were removed from, or had their reimbursement status altered within, the Primary Care Reimbursement Service systems in 2024 and 2025 which resulted in rejected claims; and to provide details of such medicines and the dates of change [28070/26]
772. Deputy Ken O'Flynn asked the Minister for Health the proportion of rejected or unpaid pharmacy claims under the general medical services scheme in 2024 and 2025 attributable to administrative or submission errors; and the measures in place to reduce such errors. [28071/26]
773. Deputy Ken O'Flynn asked the Minister for Health whether the HSE maintains any national database or registry recording clinical outcomes for patients who undergo procedures abroad under the treatment abroad scheme; if not, the reason no such system exists; and if she will outline any plans to establish one. [28074/26]
774. Deputy Ken O'Flynn asked the Minister for Health the mechanisms that are in place to ensure long-term follow-up care for patients undergoing procedures abroad under the treatment abroad scheme, and whether compliance with follow-up protocols is monitored or audited. [28076/26]
775. Deputy Ken O'Flynn asked the Minister for Health whether any audits have been conducted since 2020 on clinical outcomes or patient safety in respect of procedures funded under the treatment abroad scheme; if so, to provide details; if not, the reason none have been undertaken. [28077/26]